Pharmaceutical dosage forms comprising sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate

A method of making a solid pharmaceutical dosage form for oral administration comprising sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (active ingredient (I)), a concentration of auxiliaries having divalent and/or trivalent cations ≦0.1% based on the total mass of the formulation, a concentration of lactose ≦10% based on the total mass of the formulation and a concentration of active ingredient (I) ≧10% based on the total mass of the formulation, characterized in that

• (a) a granulate comprising the active ingredient (I) is initially prepared and
• (b) the granulate, optionally with addition of pharmaceutically acceptable auxiliaries, is then converted into the pharmaceutical dosage form.